JavedButlerMD

Cardiology • Jackson, MS

Heart Failure & Transplantation

President, Baylor Scott and White Research Institute Senior Vice President, Baylor Scott and White Health

Join to view full profile

Dr. Butler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Butler's full profile

Already have an account?

Office
2500 N State St
Jackson, MS 39216
Phone+1 601-984-1000

Fax+1 601-984-6439

Summary

Javed Butler, MD, MPH, MBA, is the President of the Baylor Scott and White Research Institute, and Senior Vice President and Maxwell A. and Gayle H. Clampitt Endowed Chair at the Baylor Scott and White Health in Dallas, TX. He is also the Distinguished Professor of Medicine at University of Mississippi in Jackson, MS. Prior to joining Baylor Scott and White Health, he served as the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi, where he was also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.
He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and a Master in Business Administration from the Emory University.
Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.

Education & Training

Vanderbilt University Medical CenterFellowship, Cardiovascular Disease, 1995 - 1998
Yale-New Haven Medical CenterResidency, Internal Medicine, 1991 - 1994
Aga Khan Medical CollegeClass of 1990

Certifications & Licensure

GA State Medical License 2006 - 2025
MS State Medical License 2018 - 2025
NY State Medical License 2014 - 2025
TN State Medical License 1999 - 2007
CT State Medical License 1994 - 1999
American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

Atlanta Magazine: Top Doctors Castle Connolly, 2009-2014
Super Doctor SuperDoctors.com
Fellow (FACC) American College of Cardiology

Clinical Trials

Heart Failure Study: The Atlanta Cardiomyopathy Consortium Start of enrollment: 2007 Nov 01
Completed
Dopamine in Acute Decompensated Heart Failure II Start of enrollment: 2009 Jul 01
Terminated
Phase 4
Cost Effectiveness and Quality of Life in Heart Failure Patients With Diabetes Start of enrollment: 2009 Sep 01
Completed
Not Applicable
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) Start of enrollment: 2013 Apr 01
Completed
Phase 2
Right Ventricular Failure After Implantation of Left Ventricular Assist Devices Start of enrollment: 2013 Jul 01
Completed
Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction Start of enrollment: 2014 Apr 01
Completed
Phase 2
A Phase IIa, Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects Wi Start of enrollment: 2014 Jun 01
Get With the Guidelines-Stroke Registry Start of enrollment: 2003 Jan 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

Machine learning in the prevention of heart failure.
Arsalan Hamid, Matthew W Segar, Biykem Bozkurt, Carlos Santos-Gallego, Vijay Nambi
Heart Failure Reviews. 2025-01-01
Design and rationale of a pragmatic randomized clinical trial of early dronedarone versus usual care to change and improve outcomes in persons with first-detected atri...
Sean D Pokorney, Hayley Nemeth, Karen Chiswell, Christine Albert, Nadine Allyn
American Heart Journal. 2025-01-01
In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure.
Muhammad Sameer Arshad, Adeena Jamil, Stephen J Greene, Harriette G C Van Spall, Gregg C Fonarow
Heart Failure Reviews. 2025-01-01

Journal Articles

Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults with Diabetes
Michael C Honigberg, Ravi B Patel, Javed Butler, Darren K Mcguire, JAMA Cardiology
Effect of a Self-Care Intervention on 90-Day Outcomes in Patients with Acute Heart Failure Discharged from the Emergency Department
Phillip D Levy, Deborah J Diercks, Gregory J Fermann, Brian Hiestand, Joann Lindenfeld, Jennifer Martindale, Javed Butler, JAMA Cardiology
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical Practice
Muthiah Vaduganathan, Javed Butler, Paul A Heidenreich, Michelle M Kittleson, Anjali Tiku Owens, Pamela N Peterson, Clyde W Yancy, Gregg C Fonarow, JAMA Cardiology
Effect of Vericiguat vs Placebo on Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction
Robert O Blaustein, Javed Butler, JAMA
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Javed Butler, Ileana Pina, New England Journal of Medicine
Heart Failure Epidemiology in Patients with Diabetes Mellitus Without Coronary Heart Disease
James L Januzzi, Darren K Mcguire, Javed Butler, Journal of Cardiac Failure
Clinical Research History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure
Javed Butler, Margaret M Redfield, Adrian F Hernandez, Muthiah Vaduganathan, Ravi B Patel, Sanjiv J Shah, ScienceDirect
Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United States
Javed Butler, John A Spertus, Gregg C Fonarow, Journal of Cardiac Failure
Definitions of Stage D Heart Failure and Outcomes Among Outpatients with Heart Failure and Reduced Ejection Fraction
Jeffrey S Hedley, Andrew A Mccue, Javed Butler, International Journal of Cardiology
State-of-the-Art Paper Antihyperglycemic Therapies to Treat Patients with Heart Failure and Diabetes Mellitus
Robert J Mentz, Javed Butler, ScienceDirect
Clinical Research INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients with Heart Failure and Reduced Ejection Fraction
Andrew A McCue, Javed Butler, Jeffrey S Hedley, ScienceDirect
Original Investigation Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry
John A Spertus, Javed Butler, Nancy M Albert, Adam D DeVore, Gregg C Fonarow, Laine Thomas, Adrian F Hernandez, ScienceDirect
Perspective Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure with Preserved Ejection Fraction: A Systematic Review
Muthiah Vaduganathan, Javed Butler, Sonali Kumar, ScienceDirect
Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients with Heart Failure
Adrian F. Hernandez, Greg C. Fonarow, Nancy M. Albert, Laine Thomas, John A. Spertus, Adam D. DeVore, Javed Butler, JACC: Cardiovascular Imaging
Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure
Javed Butler, John R Teerlink, Lukasz P Cerbin, Adam D DeVore, Randall C Starling, Adrian F Hernandez, Robert J Mentz, ScienceDirect
Mini-Focus Issue: Exercise Performance and Cardiac Rehabilitation Relative Impairments in Hemodynamic Exercise Reserve Parameters in Heart Failure with Preserved Eject...
Barry A Borlaug, Dalane W Kitzman, Rohan Khera, Gregory D Lewis, Javed Butler, ScienceDirect
Join now to see all

Lectures

Heart Failure Prevention for All
Heart Failure Society of America, Bloomington, Minnesota - 9/27/2012
Guideline Directed Management of a NYHA Class III Patient: How to Titrate What to Avoid Tools for Success and Practical Pearls
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Selecting A First-Choice Therapy For Systolic HF: The Growing Body of Evidence
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019

Authored Content

Trends in HF Hospitalizations Among Young Adults in the United States from 2004 to 2018May 2022
Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureAugust 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureAugust 2020
Heart Failure Epidemiology in Patients with Diabetes Mellitus Without Coronary Heart DiseaseNovember 2018
Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United StatesSeptember 2018
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients with Type 2 DiabetesMarch 2018
2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction A Report of the American College of Cardiology Task Force on Expert Consensus Decision PathwaysJanuary 2018
2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction A Report of the American College of Cardiology Task Force on Expert Consensus Decision PathwaysJanuary 2018
2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure TreatmentDecember 2017
2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection FractionDecember 2017
Join now to see all

Press Mentions

URMC to Lead $27M Heart Failure Medication StudyAugust 13th, 2024
Effect of Dapagliflozin on Health Status in Patients with Preserved or Mildly Reduced Ejection FractionDecember 14th, 2022
Adding Salt to Foods and Risk of Cardiovascular DiseaseDecember 1st, 2022
Join now to see all